Lovastatin interacts with natural products to influence cultured hepatocarcinoma cell (Hep-G2) growth

Journal of the American College of Nutrition

Volumn 29, Issue 3, 2010, Pages 204-210

  Popovich, David G ^a   Tiaras, Felicia ^a   Yeo, Chia Rou ^a   Zhang, Wei ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Capsaicin; Curcumin; Epigallocatechin gallate; Hep G2; Isobolographic analysis; Lovastatin; Synergy

Indexed keywords

CAPSAICIN; CURCUMIN; EPIGALLOCATECHIN GALLATE; MEVINOLIN;

ARTICLE; CELL GROWTH; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LC 50;

ANTINEOPLASTIC AGENTS; CAPSAICIN; CARCINOMA, HEPATOCELLULAR; CATECHIN; CELL LINE, TUMOR; CELLS, CULTURED; CURCUMIN; DRUG SYNERGISM; HEP G2 CELLS; HERB-DRUG INTERACTIONS; HUMANS; LIVER NEOPLASMS; LOVASTATIN; PLANT EXTRACTS;

EID: 77957909924     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2010.10719835     Document Type: Article

References (30)

1. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, Grundy SM, Johnson CL: Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA 294:1773–1781, 2005.
2. Corsini A, Maggi FM, Catapano AL: Pharmacology of competitive inhibitors of HMg-CoA reductase. Pharmacol Res 31:9–27, 1995.
3. Barnes PM, Bloom B, Nahin RL: Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report, 1–23, 2009.
4. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118, 2005.
5. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD: Continuation of statin treatment and all-causemortality: a populationbased cohort study. Arch Intern Med 169:260–268, 2009.
6. Friis S, Olsen JH: Statin use and cancer risk: an epidemiologic review. Cancer Invest 24:413–424, 2006.
7. Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H: Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors: synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 43:808–816, 2005.
8. Gauthaman K, Manasi N, Bongso A: Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol 157:362-373, 2009.
9. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR: Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5:2223–2229, 1999.
10. Sanchez AM, Sanchez MG, Malagarie-Cazenave S, Olea N, Diaz-Laviada I: Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin. Apoptosis 11:89–99, 2006.
11. Poynter JN, Gruber SB, Higgins PDR, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G: Statins and the risk of colorectal cancer. N Engl J Med 352:2184–2192, 2005.
12. El-Serag HB, Johnson ML, Hachem C, Morgana RO: Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136:1601-1608, 2009.
13. Argo CK, Loria P, Caldwell SH, Lonardo A: Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48:662-669, 2008.
14. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB: Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867–1872, 2002.
15. Cao J, Liu Y, Jia L, Zhou HM, Kong Y, Yang G, Jiang LP, Li QJ, Zhong LF: Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radic Biol Med 43:968–975, 2007.
16. Inaba H, Nagaoka Y, Kushima Y, Kumagai A, Matsumoto Y, Sakaguchi M, Baba K, Uesato S: Comparative examination of anti-proliferative activities of (-)-epigallocatechin gallate and (–)-epigallocatechin against HCT116 colorectal carcinoma cells. Biol Pharm Bull 31:79–84, 2008.
17. Tallarida RJ: Drug synergism: its detection and applications. J Pharmacol Exp Ther 298:865–872, 2001.
18. Tallarida RJ, Porreca F, Cowan A: Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci 45:947–961, 1989.
19. Popovich DG, Yeo SY, Zhang W: Ginseng (Panax quinquefolius) and licorice (Glycyrrhiza uralensis) root extract combinations increase hepatocarcinoma cell (Hep-G2) viability. Evid Based Complement Alternat Med, in press.
20. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC: Breast cancer growth prevention by statins. Cancer Res 66:8707–8714, 2006.
21. Yang CS, Lambert JD, Ju J, Lu G, Sang S: Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol 224:265–273, 2007.
22. Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A: Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem 16:1451–1462, 2009.
23. Reilly CA, Taylor JL, Lanza DL, Carr BA, Crouch DJ, Yost GS: Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors. Toxicol Sci 73:170–181, 2003.
24. Holstein SA, Hohl RJ: Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1:141–149, 2001.
25. Pandak WM, Stravitz RT, Lucas V, Heuman DM, Chiang JY: Hep G2 cells: a model for studies on regulation of human cholesterol 7alpha-hydroxylase at the molecular level. Am J Physiol 270:G401–G410, 1996.
26. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115:959–968, 2005.
27. Zhou Y, Doyen R, Lichtenberger LM: The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid. Biochim Biophys Acta 1788:507-513, 2009.
28. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE: Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos 21:1003–1011, 1993.
29. Tang BK, Kalow W: Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4. Eur J Clin Pharmacol 47:449–451, 1995.
30. Cheng Y, Kozubek A, Ohlsson L, Sternby B, Duan RD: Curcumin decreases acid sphingomyelinase activity in colon cancer Caco-2 cells. Planta Med 73:725–730, 2007.